Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2010
12/23/2010US20100324047 Raf kinase modulators and methods of use
12/23/2010US20100324046 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
12/23/2010US20100324043 Bicyclic And Tricyclic Compounds As KAT II Inhibitors
12/23/2010US20100324041 Pyrrolopyridines as kinase inhibitors
12/23/2010US20100324040 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5- amine derivatives and their use for the treatment of cancer
12/23/2010US20100324038 Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
12/23/2010US20100324036 Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
12/23/2010US20100324026 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
12/23/2010US20100324009 Substituted Sulfonamide Compounds
12/23/2010US20100324007 Oral suspension of prednisolone acetate
12/23/2010US20100324001 Novel Methods for the Treatment of Inflammatory Diseases
12/23/2010US20100323999 Therapeutic Molecules and Methods-1
12/23/2010US20100323997 Novel uses
12/23/2010US20100323994 Substituted imidazopyridazines useful as kinase inhibitors
12/23/2010US20100323990 Ship 1 modulator prodrugs
12/23/2010US20100323981 Treatment of statin side effects
12/23/2010US20100323977 Mucoadhesive nanoparticles for cancer treatment
12/23/2010US20100323974 Inhibitors of PARP Activity and Uses Thereof
12/23/2010US20100323973 Conjugates containing hydrophilic spacer linkers
12/23/2010US20100323971 Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
12/23/2010US20100323970 Sap variants and their use
12/23/2010US20100323969 Compounds Binding to P-Selectin
12/23/2010US20100323967 RNA Antagonist Compounds for the Modulation of MCL-1
12/23/2010US20100323964 New non-selective somatostatin analogues
12/23/2010US20100323963 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
12/23/2010US20100323957 Novel assay for inhibitors of egfr
12/23/2010US20100323950 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
12/23/2010US20100323949 erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof
12/23/2010US20100323041 Methods and therapeutic compositions comprising plant extracts for the treatment of cancer
12/23/2010US20100323038 Pharmaceutical Compositions
12/23/2010US20100323034 Method for determination of sensitivity to anti-cancer agent
12/23/2010US20100323033 Cancer sensitizer comprising chlorogenic acid
12/23/2010US20100323030 Composition with Anti-Inflammatory, Protein Synthesizing, Enzyme Deficiency Activating Genetic Therapy and Anti-Cancer Activity and Methods of Use
12/23/2010US20100323027 Mesenchymal stem cell conditioned medium
12/23/2010US20100323021 Antitumoral treatments
12/23/2010US20100323020 Stable nanoparticulate drug suspension
12/23/2010US20100323004 Non-pegylated liposomal doxorubicin triple combination therapy
12/23/2010US20100323002 Inhibition of melanogenesis and melanoma metastasis with p-amino benzoic acid (paba)
12/23/2010US20100322992 Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device
12/23/2010US20100322991 Honokiol analogs and their use in treating cancers
12/23/2010US20100322979 Peptidomimetic Resorbable Peptide-Polymer Hybrid Polyester Nanoparticles
12/23/2010US20100322978 Medical composition
12/23/2010US20100322974 Targeting the histone code as a bacterial strategy for selectively modulating gene expression
12/23/2010US20100322968 Therapeutic agent for cancer
12/23/2010US20100322966 Method for allogeneic cell therapy
12/23/2010US20100322963 Low dose inoculation with tap for anti-tumor immunity
12/23/2010US20100322953 Lipidated Tumor-Associated Antigens and Immunotherapeutic Compositions
12/23/2010US20100322951 Replication-proficient dsRNA capsids and uses thereof
12/23/2010US20100322950 Compositions and methods for diagnosis and treatment of tumors
12/23/2010US20100322949 Methods for diagnosing and treating astrocytomas
12/23/2010US20100322946 Multispecific antibodies
12/23/2010US20100322945 Immunogenic compounds and protein mimics
12/23/2010US20100322940 In vitro modification of glycosylation patterns of recombinant glycopeptides
12/23/2010US20100322939 Novel methods for treating egfr-associated tumors
12/23/2010US20100322937 EGF receptor epitope peptides and uses thereof
12/23/2010US20100322936 Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
12/23/2010US20100322935 Tri- or Tetraspecific Antibodies
12/23/2010US20100322934 Bispecific, Tetravalent Antigen Binding Proteins
12/23/2010US20100322933 Intraoperative trifunctional antibody application for prophylaxis of intraperitoneal tumor cell dissemination
12/23/2010US20100322931 Anti-vegf antibodies and their uses
12/23/2010US20100322930 Fibronectin-based binding molecules and their use
12/23/2010US20100322929 Antigen presenting cell targeted cancer vaccines
12/23/2010US20100322927 Glycosylated antibodies
12/23/2010US20100322924 Humanized Fc gamma RIIB-Specific Antibodies And Methods Of Use Thereof
12/23/2010US20100322922 Neutralization of CD95 Activity Blocks Invasion of glioblastoma Cells In Vivo
12/23/2010US20100322920 Human monoclonal antibodies against CD30
12/23/2010US20100322917 Pharmaceutical composition containing arazyme for the prevention of liver dysfunction
12/23/2010US20100322914 Prodrug anti-cancer therapy
12/23/2010US20100322910 Methods of obtaining antigen-specific t cell populations
12/23/2010US20100322909 Th1-associated micrornas and their use for tumor immunotherapy
12/23/2010US20100322905 Compositions and methods for treating pancreatic cancer
12/23/2010US20100322898 Methods of treating cancer using il-21
12/23/2010US20100322896 Molecular adjuvant
12/23/2010US20100322895 T cell depleting compositions useful for treating cancer
12/23/2010US20100322862 Methods and compositions using peptides and proteins with c-terminal elements
12/23/2010US20100322856 Compositions and Methods for Inducing Angiogenesis
12/23/2010US20100322855 Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
12/23/2010US20100322853 Nanoparticulate compositions of angiogenesis inhibitors
12/23/2010US20100322852 Nanoparticulate compositions of angiogenesis inhibitors
12/23/2010US20100322851 KID3 and KID3 Antibodies That Bind Thereto
12/23/2010US20100322849 Enhanced b cell cytotoxicity of cdim binding antibody
12/23/2010CA2765870A1 Renal cell carcinoma biomarkers
12/23/2010CA2765792A1 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
12/23/2010CA2765770A1 Agents and uses thereof
12/23/2010CA2765755A1 Anti-vegf antibodies and their uses
12/23/2010CA2764542A1 Disubstituted phthalazine hedgehog pathway antagonists
12/23/2010CA2762458A1 New therapeutical uses of inecalcitol
12/22/2010EP2264457A1 Method for diagnosing non-small cell lung cancers
12/22/2010EP2264190A1 Method for diagnosing non-small cell lung cancers
12/22/2010EP2264187A1 Method for diagnosing non-small cell lung cancers
12/22/2010EP2264186A1 Method for diagnosing non-small cell lung cancers
12/22/2010EP2264185A1 Method for diagnosing non-small cell lung cancers
12/22/2010EP2264173A2 Use of a double-stranded ribonucleic acid for targeted inhibition of the expression of a given target gene
12/22/2010EP2264172A1 Oligomeric compounds for the modulation of HIF-1alpha expression
12/22/2010EP2264072A1 Enhancement of antibody-mediated cytotoxicity.
12/22/2010EP2264070A1 Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody
12/22/2010EP2264059A1 Polypeptides, cDNAs encoding the same and utilization thereof
12/22/2010EP2264034A1 Bicyclic pyrrole compound
12/22/2010EP2264033A1 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
12/22/2010EP2264028A1 Pyrazole compounds useful as protein kinase inhibitors
1 ... 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 ... 2211